



## PRESS RELEASE

---

### **Cooper-Vemedica acquires product portfolio from Sanofi**

---

Kortrijk (Belgium), 17 April 2018

#### **Cooper-Vemedica acquires product portfolio from Sanofi**

Damier NV, the investment vehicle of Yvan Vindevogel, and Charterhouse Capital Partners LLP today announce that Cooper-Vemedica (“the Company”), a leading European OTC drug manufacturer and distributor, has acquired a portfolio of 12 pharmaceutical brands from Sanofi S.A. (“Sanofi”) for an amount of €158m.

The products are split across the Dermatology, Well-being, Eye Care and other fields and are predominately sold in France and Italy, as well as exported to other markets around the world. The portfolio includes a number of well-established, market-leading brands, which are highly complementary to Cooper-Vemedica’s existing diversified product range.

This acquisition represents the next step in the Cooper-Vemedica Group’s strategy to create a pure-play OTC pan-European leader.

Yvan Vindevogel, CEO of Damier NV, said:

*“We fully support the management of the Company in pursuing a growth plan by external and geographical growth. The acquired brands will lead to sufficient scale for the Company’s Italian business and add some very well-know brands ( f.i. Hexomedine) to the portfolio in France”.*

Francis Doblin, CEO of Cooper-Vemedica, said:

*“The acquisition of these strong brands, each with high consumer awareness and leading market positions, will further strengthen Cooper’s position in Europe. We are convinced that Cooper- Vemedica will successfully integrate these brands into its existing network to further fulfil its potential as an international leader in the OTC space”.*

Alan Main, Head of Consumer Healthcare, Sanofi said:

*“The divestment of these non-core products is aligned with our growth model strategy to focus on four core categories of Pain; Allergy, Cough & Cold; Digestive Health and Nutritionals and reduce the complexity of our portfolio. It allows us to focus more strongly around global and some core local brands and drives the correct balance between achieving the efficiencies that come with global scale, while ensuring we have the breadth of portfolio to win locally”.*



### **About Charterhouse Capital Partners LLP**

Charterhouse is one of the longest established private equity firms operating in Europe.

The firm invests in companies headquartered in Western Europe and works closely with incumbent management teams, backing them and providing active support to drive growth. Charterhouse pursues a highly selective investment approach, partnering with a small number of high-quality companies. Transaction values range from €250mn to €2bn.

Charterhouse is based in London and has a deep bench of experienced investment professionals. Since inception Charterhouse has completed over 140 transactions worth an aggregate value of over €50bn. [www.charterhouse.co.uk](http://www.charterhouse.co.uk)

### **About Cooper-Vemedia**

Cooper-Vemedia is a leading independent pan-European OTC drug manufacturer and distributor, with a key presence in six European OTC domestic markets and various export countries worldwide. It operates with a unique distribution network tailored to each local market. It benefits from a diversified product portfolio in various speciality segments, including leading and sizable international brands benefitting strong brand awareness. It has approximately 730 full-time employees. For more information, visit [www.cooper.fr](http://www.cooper.fr) and [www.vemedia.com](http://www.vemedia.com)

### **About Damier**

Damier is an investment vehicle that primarily focuses on investing in European companies and assets active in branded consumer sectors and more specifically in the consumer healthcare sector. Damier also focuses on acquiring or investing in well-established brands or innovative technologies in the consumer healthcare, beauty, personal care and medical devices sectors. With the recently established company Vision Healthcare ([www.visionhealthcare.eu](http://www.visionhealthcare.eu)), Damier is also actively developing a scalable direct- to- consumer healthcare company by adopting a clicks-and-bricks strategy with an emphasis on social media campaigns.

### **For additional information:**

Yvan Vindevogel	CEO Damier	+32 (0) 475 453 320	<a href="mailto:yvanvindevogel@telenet.be">yvanvindevogel@telenet.be</a>
Bernard Lemaire	CFO Damier	+32 (0) 497 050 829	<a href="mailto:bernard.lemaire@damiergroup.be">bernard.lemaire@damiergroup.be</a>